Brief: Exelixis Announces Initiation Of Stellar-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib In Combination With Pembrolizumab
04/12/2023 15:15
Dec 4 (Reuters) - Exelixis Inc EXEL.O :
* EXELIXIS ANNOUNCES INITIATION OF THE STELLAR-305 PHASE 2/3
PIVOTAL TRIAL EVALUATING ZANZALINTINIB IN COMBINATION WITH
PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED RECURRENT OR
METASTATIC HEAD AND NECK CANCER
Source text for Eikon: ID:nBw4Gctrsa
Further company coverage: EXEL.O
((reuters.briefs@thomsonreuters.com;))